<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02418819</url>
  </required_header>
  <id_info>
    <org_study_id>B7441007</org_study_id>
    <nct_id>NCT02418819</nct_id>
  </id_info>
  <brief_title>A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia</brief_title>
  <official_title>A Randomized, Double-blind, Placebo Controlled, Parallel Group, Sponsor Open, Phase 1b Study To Examine The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-06412562 In Psychiatrically Stable Subjects With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to investigate the safety, tolerability pharmacokinetics and
      pharmacodynamic effects of PF-06412562 following multiple dose administration as MR tablets
      in subjects with schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      B7441007 is a randomized, double-blind, placebo-controlled, sponsor open, parallel group
      design, Phase 1b study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of
      3 doses of PF-06412562 (3 mg BID, 9 mg BID and 45 mg BID) over 15 days in approximately 100
      psychiatrically stable (as defined by the inclusion and exclusion criteria) subjects with
      schizophrenia are on background treatment with SOC antipsychotics and other psychotropic
      medications.

      All doses will be administered twice daily, with approximately 12 hours between each dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MCCB WM (working memory) domain composite score</measure>
    <time_frame>Change from baseline at Day 13</time_frame>
    <description>Matrics Consensus Cognition Battery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Monetary Incentive Delay</measure>
    <time_frame>Change from baseline at Day 15</time_frame>
    <description>change in baseline in BOLD fMRI activation parameter estimates in anterior ventral striatum; fMRI parameter estimates refer to the 90th percentile Z statistic rather than the mean Z statistic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Columbia Suicide Severity Rating Scale</measure>
    <time_frame>Change from baseline at Day 1, Day 7 and Follow-up</time_frame>
    <description>Columbia Suicide Severity Rating Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cavg: Average plasma PF- 06412562 and PF- 06663872 concentrations at steady state</measure>
    <time_frame>Day 0, 7, 12 and 16</time_frame>
    <description>Average plasma PF- 06412562 and PF- 06663872 concentrations for each dose at times 6, and 12 hours on days 0, 7 and 12, as well as 0 hours on Day 16</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>PF-06412562 3mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06412562 3mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06412562 9mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06412562 9mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06412562 45mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06412562 45mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06412562 3mg BID</intervention_name>
    <description>PF-06412562</description>
    <arm_group_label>PF-06412562 3mg</arm_group_label>
    <other_name>PF-06412562 3mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06412562 9mg BID</intervention_name>
    <description>PF-06412562</description>
    <arm_group_label>PF-06412562 9mg</arm_group_label>
    <other_name>PF-06412562 9mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06412562 45mg BID</intervention_name>
    <description>PF-06412562</description>
    <arm_group_label>PF-06412562 45mg</arm_group_label>
    <other_name>PF-06412562 45mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects with schizophrenia both male and female

          2. Evidence of stable schizophrenia symptomatology for at least 3 months (no
             hospitalizations for schizophrenia, no increase in level of psychiatric care due to
             worsening of symptoms of schizophrenia, etc).

          3. Subjects must be in ongoing maintenance antipsychotic therapy other than clozapine
             (oral or depot) on a stable medication treatment regimen for for at least 2 months
             prior to Day 1, including concomitant psychotropic medications.

        Exclusion Criteria:

          1. History of seizure

          2. Pregnant or nursing females

          3. Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, neurologic, or allergic disease
             (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies
             at time of screening and at the time of dosing).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arcadia MRI &amp; Imaging Center</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Clinical Trials Medical Group</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glendale Adventist Medical Center</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Psychiatric Research Center (MPRC) of the University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CBH Health, LLC</name>
      <address>
        <city>Gaithersburg</city>
        <state>Maryland</state>
        <zip>20877</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foers Long Term Care Pharmacy LLC</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7441007&amp;StudyName=A%20Randomized%2C%20Double-blind%2C%20Placebo%20Controlled%2C%20Parallel%20Group%2C%20Sponsor%20Open%2C%20Phase%201b%20Study%20To%20Examine%20The%20Safety%2C%20Tolerability%2C%20Pharmacokinetics%2C%20And%20Pharmacodynamics%20Of%20Pf%2006412562%20In%20Psychiatrically%20Stable%20Subjects%20With%20Schizophrenia</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2015</study_first_submitted>
  <study_first_submitted_qc>April 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2015</study_first_posted>
  <last_update_submitted>November 18, 2016</last_update_submitted>
  <last_update_submitted_qc>November 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>August 3, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>November 13, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

